There are no items in your quote.

Skip to Main Content »

BPS Bioscience is actively developing Covid-19 research tools to support scientists in their work in validating assays, developing vaccines, and testing for antibody or drug efficacy. In addition to a series of biochemical assays used to identify inhibitors of the Spike:ACE2 interaction, BPS Bioscience has launched three new lentiviruses to the market for building cell based assays, generating cell lines, and validating the neutralizing effect of inhibitory compounds on Spike:ACE2 binding in a physiologically relevant context.

 

ACE2 Lentivirus

The ACE2 Lentivirus is replication incompetent, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. Under the control of EF1a promoter the particles contain an ACE2 gene (NM_021804.3) allowing transient expression of ACE2 in your target cell or a generation of a stable cell line expressing ACE2 using Puromycin.

Spike (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter)

Due to its interaction with the Human ACE2 , the coronavirus Spike protein is involved in the first step of the viral replication which is the attachment of the virus to the host cell. To advance research of this Spike:ACE2 interaction, BPS Bioscience has developed the Spike (SARS-CoV-2) Pseudotyped Lentivirus. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, to easily measure spike-mediated entry into target cells via luciferase reporter activity. The Spike protein includes the entire extracellular domain to allow studies of S1-S2 cleavage as well as receptor binding.

Bald Lentiviral Pseudovirion (Luciferase Reporter)

The Bald Lentiviral Pseudovirion was produced without envelope glycoproteins such as VSV-G or SARS-CoV-2 spike. It contains the firefly luciferase gene driven by a CMV promoter as the reporter. The bald lentiviral pseudovirion can serve as a negative control when studying virus entry initiated by specific interactions between virus particles and receptors.

Related Recombinant Cell Lines

 

 


BPS is once again on the leading edge of life science research!  They have just released over 50 new products, including 27 products for Coronavirus research. These include several unique assay kits to discover new drug candidates and a  pseudovirus that can be used in a reporter assay to study viral attachment and entry into human cells.  Scientists across the globe are frantically working to develop new therapeutics and vaccines to treat/prevent COVID-19, so we know you’ll want to see this information. 

 Meanwhile, you can see our full portfolio of coronavirus products and services here:

 

https://bpsbioscience.com/research-areas/coronavirus

 

https://bpsbioscience.com/coronavirus-screening-profiling

 

 

 

 

Cat. #

Name

Size

Storage/ Shipping

Description

Coronavirus 

79923

ACE2 Inhibitor Screening Assay Kit

96 rxns.

Mixed Storage/

dry ice

The ACE2 Inhibitor Screening Assay Kit is designed to measure the exopeptidase activity of ACE2 for screening and profiling applications. The ACE2 assay kit comes in a convenient 96-well format, with purified ACE2, its substrate, and ACE2 buffer for 96 reactions.

79936

ACE2:SARS-CoV-2 Spike Inhibitor Screening Assay Kit

96 rxns.

Mixed Storage/

dry ice

The ACE2:SARS-CoV-2 Spike Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of the interaction between the ACE2 and Spike proteins.  This kit is useful for screening for inhibitors of ACE2 binding to SARS-CoV-2 Spike.

79945

ACE2:SARS-CoV-2 Spike S1 Inhibitor Screening Assay Kit

96 rxns.

Mixed Storage/

dry ice

The ACE2:SARS-CoV-2 Spike S1 Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of this interaction. This kit comes in a convenient 96-well format, with purified ACE2 and SARS-CoV-2 Spike S1 proteins, Streptavidin-HRP, and buffer for 100 binding reactions.

79931

SARS-CoV-2 Spike:ACE2 Inhibitor Screening Assay Kit

96 rxns.

Mixed Storage/

dry ice

The SARS-CoV-2 Spike:ACE2 Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of the interaction between the Spike and ACE2 proteins.  This kit is useful for screening for inhibitors of SARS-CoV-2 Spike binding to ACE2.

79949

SARS-CoV-2 Spike S1-Biotin: ACE2 TR-FRET Assay Kit

384 rxns.

Mixed storage/

dry ice

The SARS-CoV-2 Spike S1:ACE2 TR-FRET Assay is designed to measure the inhibition of the binding between SARS-CoV-2 Spike S1 and human ACE2 in a homogeneous 384 reaction format. This TR-FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications.

79954

Spike S1 (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit

96 rxns.

Mixed storage/

dry ice

The SARS-CoV-2 Spike S1:ACE2 Inhibitor Screening Colorimetric Assay Kit is designed for screening and profiling inhibitors of this interaction. This kit comes in a convenient 96-well format, with purified SARS-CoV-2 Spike S1 and ACE2-Biotin proteins, streptavidin-HRP, and assay buffer for 100 binding reactions.

79955

3CL Protease (SARS-CoV-2) Assay Kit

96 rxns.

Mixed storage/

dry ice

The 3CL Protease Assay Kit is designed to measure 3CL Protease activity for screening and profiling applications, in a homogeneous assay with no time-consuming washing steps. The kit comes in a 96-well format, with purified 3CL Protease, fluorogenic substrate, and buffer for 100 enzyme reactions. 3CL inhibitor GC376 is included as an inhibitor control.

79942

Spike (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter)

500 µl x 2

-80°C/

dry ice

The SARS-CoV-2 Spike Pseudotyped Lentivirus produced with SARS-CoV-2 Spike (GenBank #QHD43416.1) as the envelope glycoproteins instead of VSV-G. These pseudovirions also contain the firefly luciferase gene driven by a CMV promoter, so spike-mediated cell entry can be measured via luciferase reporter activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to study the mechanism of viral transduction and screen for neutralizing antibodies for Spike.

79943

Bald Lentiviral Pseudovirion (Luciferase Reporter)

500 µl x 2

-80°C/

dry ice

The bald lentiviral pseudovirion was produced without envelope glycoproteins such as VSV-G or SARS-CoV-2 spike. It contains the firefly luciferase gene driven by a CMV promoter as the reporter. The bald lentiviral pseudovirion can serve as a negative control when studying virus entry initiated by specific interactions between virus particles and receptors.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     

 

 

 

Cat. #

Name

Size

Storage/ Shipping

Description

Image result for coronavirus clear backgroundCoronavirus 

100696-1

Spike S1 RBD, Avi-His-tag (SARS-CoV-2)

100 µg

-80°C/

dry ice

SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank #QHD43416.1, a.a. 319-541, with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 29 kDa.

100696-2

1 mg

100719-1

Spike S1 (16-685), Fc Fusion, Avi-tag (SARS-CoV-2)

100 µg

Image result for coronavirus clear background-80°C/

dry ice

Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank #QHD43416.1, a.a. 16-685, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag™, expressed in a HEK293 expression system, MW=104 kDa.

100719-2

1 mg

100720-1

Spike S1 (16-685), Fc Fusion, Avi-tag, Biotin-labeled (SARS-CoV-2)

25 µg

-80°C/

dry ice

Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank #QHD43416.1, a.a. 16-685, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag, expressed in a HEK293 expression system enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=104 kDa.

100720-2

50 µg

100678-1

Spike S1 (13-665), Fc Fusion, Avi-tag (SARS-CoV-2)

100 µg

-80°C/

dry ice

Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank #QHD43416.1, a.a. 13-665, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag™, expressed in HEK293 cells, MW=102 kDa.

100678-2

1 mg

100679-1

Spike S1 (13-665), Fc fusion, Avi-tag, Biotin-Labeled (SARS-CoV-2)

20 µg

-80°C/

dry ice

 

Human Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank #QHD43416.1, a.a. 13-665, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag, expressed in HEK293 cells and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is ≥90%. MW=102 kDa.

100679-2

50 µg

100687-1

Spike S1 RBD, His-tag (SARS-CoV-2)  

50 µg 

Image result for coronavirus clear background-80°C/

dry ice

2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank #QHD43416.1, a.a. 319-541, with C-terminal His-tag, expressed in CHO cells. MW= 39 kDa.

100687-2 

100 µg 

100699-1